Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine.
This report describes a patient who developed pulmonary toxicity, manifest by dyspnea on exertion, a low pO2, a normal FEV1 and FVC, and a low DLCO while receiving 5-fluoro-2'-deoxyuridine (FUDR) by intermittent continuous i.v. infusion. No other cause of his low DLCO could be identified. The dyspnea on exertion and DLCO improved gradually after the FUDR was discontinued. This case was felt to represent a previously undescribed toxicity of the continuous i.v. infusion of FUDR.
Chu
S I
SI
Department of Medicine, University of Minnesota Medical School, Minneapolis 55455, USA.
Kim
H J
HJ
Skubitz
K M
KM
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D005467:Floxuridine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000188:drug therapy; D008171:Lung Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012129:Respiratory Function Tests
D005467:Floxuridine; D011241:Prednisone